Human Transient Expression Technology

Cevec Pharmaceuticals introduced the Cap-T transient expression system for fast, serum-free and high yield protein production. With the system customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it a tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization. CEO Dr. Rainer Lichtenberger comments: Starting with transient protein expression using CAP-T and moving forward with stable expression using Cap cells, Cevec is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.